4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

Biotechnology

Healthcare
$10.46 +1.70%

+$0.16 today

Market cap
$577.85M
Beta
2.76
P/E (TTM)
-4.0
EPS (TTM)
-$2.36
52W Low $3.68High $12.34

Volume 0.68M

Average 0.77M

FDMT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

4D Molecular Therapeutics, Inc.NASDAQ: FDMT

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $64.98M rose 59.7% year over year, ahead of the +42.7% change in trailing-twelve-month research & development. Sequentially, it rose 12.8% from the prior quarter. Over 3 fiscal years it compounded at +34.6% a year.

Context

  • Research & development amounted to 229.7% of revenue in FY2025, down 381659.5 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +59.7% holds above the trailing-twelve-month pace of +42.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$64.98M+12.8% QoQ
Last fiscal yearDec 2025
$195.7M+38.5% YoY
LTMMar 2026
$219.98M+42.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+59.7%——
1 year+38.5%——
3-year CAGR+34.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
195.7M USD
Year-over-year change
+38.5%
4-year CAGR
+33.6%

Research & Development vs competitors

How FDMT compares with its peers on the latest reported figures

  • FDMT's LTM Mar 2026 research & development of $219.98M is the 2nd highest of the 8 companies compared; the peer median is $128.82M.
  • Its year-over-year change of +42.7% is the 2nd highest of 8, against a peer median of +9.2%.
  • Research & development amounts to 249.3% of revenue for FDMT, versus a peer median of 260.4%.
FDMT Competitors Peer median
Research & Development for FDMT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RGNXREGENXBIO Inc.LTM Mar 2026$228.65M +12.8%-2.0%260.4%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$219.98M +42.7%+34.6%249.3%
SLDBSolid Biosciences Inc.LTM Mar 2026$155.55M +43.4%+21.4%—
QUREuniQure N.V.LTM Mar 2026$132.76M -4.7%-10.7%733.7%
MGTXMeiraGTx Holdings plcLTM Mar 2026$128.82M +9.2%+14.8%161.5%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$62.33M -17.5%+9.1%—
OCGNOcugen, Inc.LTM Mar 2026$41.48M +19.1%-10.9%928.9%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$26.43M -28.8%-2.5%181.7%
Peer median (excluding FDMT) $128.82M+9.2%-2.0%260.4%

Competitors are the stored peer set for FDMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.04M3.13M20.72M37K85.21M
Cost of Revenue61.36M80.25M97.1M141.3M7.63M
Gross Profit(43.32M)(77.12M)(76.37M)(141.26M)77.58M
Gross Margin-240.2%-2464.8%-368.5%-381789.2%91.1%
Research & Development61.36M80.25M97.1M141.3M195.7M
Selling, General & Admin28.01M32.91M36.49M46.58M49.06M
Operating Expenses28.01M32.91M36.49M46.58M237.13M
Depreciation & Amortization1.52M2.4M4.2M6.71M7.63M
EBITDA(69.79M)(105.09M)(96.63M)(154.16M)(132.48M)
EBITDA Margin-386.9%-3358.6%-466.3%-416656.8%-155.5%
Operating Income(71.33M)(110.03M)(112.87M)(187.84M)(159.55M)
Operating Margin-395.5%-3516.5%-544.6%-507678.4%-187.2%
Interest Income137K2.57M12.21M27.05M19.48M
Interest Expense00000
Other Income / Expenses16K2.54M12.03M26.97M19.44M
Income Before Tax(71.32M)(107.49M)(100.84M)(160.87M)(140.11M)
Pre-Tax Margin-395.4%-3435.4%-486.6%-434778.4%-164.4%
Income Tax Expense00000
Net Income(71.32M)(107.49M)(100.84M)(160.87M)(140.11M)
Net Margin-395.4%-3435.4%-486.6%-434778.4%-164.4%
EPS (Basic)(2.46)(3.12)(2.58)(2.98)(2.42)
EPS (Diluted)(2.46)(3.12)(2.58)(2.98)(2.42)
Weighted Avg Shares27.73M32.35M39.13M53.94M57.93M
Weighted Avg Shares (Diluted)27.73M32.35M39.13M53.94M57.93M

4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

Intrinsic Alpha fair value

Locked

Current Price

$10.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.